Atlas Trials

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Clinical trial NCT07471815 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07471815
Sponsor
Harbin Medical University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer Triple Negative Breast Cancer
Start date
2026-03-04
Primary completion
2028-03-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.